Growth Hormone Use in Adults With Prader-Willi Syndrome

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2007 by Children's Mercy Hospital Kansas City.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Children's Mercy Hospital Kansas City
ClinicalTrials.gov Identifier:
NCT00444964
First received: March 6, 2007
Last updated: March 7, 2007
Last verified: March 2007
  Purpose

The main research question this protocol aims to answer is whether treatment with growth hormone will impact body composition, quality of life, and energy balance in PWS adults, and if there is a loss of effects after cessation of treatment for at least 12 months.


Condition Intervention Phase
Prader-Willi Syndrome
Drug: Nutropin AQ
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Growth Hormone Use in Adults With Prader-Willi Syndrome

Resource links provided by NLM:


Further study details as provided by Children's Mercy Hospital Kansas City:

Primary Outcome Measures:
  • Increased IGF-1 as a function of human growth hormone dosage compared with baseline
  • Improvement of indicators or risk factors for co-morbid diseases [diabetes (by measuring insulin and glucose levels), cardiovascular disease (by measuring lipids and fatty acids), and pulmonary function] in participants.
  • Improvement in quality of life measures as indicated by ratings on established behavior checklists in participants.
  • Changes in body composition (decreased fat, increased lean body mass and bone density) as determined by DEXA in participants.
  • Increased energy expenditure as determined by whole-room calorimeter measures (8 hour energy expenditure, RMR, TEF, mechanical work); diet records, physical activity monitors and strength measures

Estimated Enrollment: 10
Study Start Date: April 2005
Estimated Study Completion Date: February 2007
Detailed Description:

The main research question this protocol aims to answer is whether treatment with growth hormone will impact body composition, quality of life, and energy balance in PWS adults, and if there is a loss of effects after cessation of treatment for at least 12 months. Specific outcomes to be evaluated are as follows:

• Increased IGF-1 as a function of human growth hormone dosage compared with baseline.

  1. Improvement of indicators or risk factors for co-morbid diseases [diabetes (by measuring insulin and glucose levels), cardiovascular disease (by measuring lipids and fatty acids), and pulmonary function] in participants.
  2. Improvement in quality of life measures as indicated by ratings on established behavior checklists in participants.
  3. Changes in body composition (decreased fat, increased lean body mass and bone density) as determined by DEXA in participants.
  4. Increased energy expenditure as determined by whole-room calorimeter measures (8 hour energy expenditure, RMR, TEF, mechanical work); diet records, physical activity monitors and strength measures.
  Eligibility

Ages Eligible for Study:   16 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 16 to 60 years old
  • Male or female with diagnosed Prader-Willi syndrome confirmed by genetic testing (e.g., mPCR)
  • Low IGF-1 level (e.g.,≤25%) at baseline
  • Ability to provide informed consent or availability of a suitable legally authorized representative

Exclusion Criteria:

  • Pregnancy
  • Previous treatment with growth hormone
  • Uncontrolled endocrine disease, (i.e. diabetes or thyroid)
  • History of severe scoliosis
  • Heart disease
  • Uncontrolled high blood pressure or history of stroke
  • Morbid obesity (using PWS growth charts)
  • Severe sleep apnea or known breathing difficulties/obstruction (as per history or diagnostic testing results
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00444964

Locations
United States, Missouri
The Children's Mercy Hospital Recruiting
Kansas City, Missouri, United States, 64108
Contact: Merlin G Butler, MD    816-234-3290    mgbutler@cmh.edu   
Contact: Wayne Moore, MD    816-234-3844    wmoore@cmh.edu   
Principal Investigator: Merlin G Butler, MD         
Sponsors and Collaborators
Children's Mercy Hospital Kansas City
Investigators
Principal Investigator: Merlin G Butler, MD The Children's Mercy Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00444964     History of Changes
Other Study ID Numbers: 303-C02R
Study First Received: March 6, 2007
Last Updated: March 7, 2007
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Syndrome
Prader-Willi Syndrome
Disease
Pathologic Processes
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Obesity
Overnutrition
Nutrition Disorders

ClinicalTrials.gov processed this record on September 18, 2014